AU2013256558B2 - Bromocriptine formulations - Google Patents

Bromocriptine formulations Download PDF

Info

Publication number
AU2013256558B2
AU2013256558B2 AU2013256558A AU2013256558A AU2013256558B2 AU 2013256558 B2 AU2013256558 B2 AU 2013256558B2 AU 2013256558 A AU2013256558 A AU 2013256558A AU 2013256558 A AU2013256558 A AU 2013256558A AU 2013256558 B2 AU2013256558 B2 AU 2013256558B2
Authority
AU
Australia
Prior art keywords
bromocriptine
tablet
bromocriptine mesylate
mesylate
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013256558A
Other languages
English (en)
Other versions
AU2013256558A1 (en
Inventor
Craig Michael Bowe
Anthony Cincotta
Paul Clark Stearns
Laura Jean Weston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Veroscience LLC
Original Assignee
Veroscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veroscience LLC filed Critical Veroscience LLC
Publication of AU2013256558A1 publication Critical patent/AU2013256558A1/en
Application granted granted Critical
Publication of AU2013256558B2 publication Critical patent/AU2013256558B2/en
Priority to AU2016202572A priority Critical patent/AU2016202572B2/en
Priority to AU2018203021A priority patent/AU2018203021B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2013256558A 2012-04-30 2013-04-29 Bromocriptine formulations Ceased AU2013256558B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2016202572A AU2016202572B2 (en) 2012-04-30 2016-04-22 Bromocriptine formulations
AU2018203021A AU2018203021B2 (en) 2012-04-30 2018-05-01 Bromocriptine formulations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/460,452 2012-04-30
US13/460,452 US8431155B1 (en) 2012-04-30 2012-04-30 Bromocriptine formulations
PCT/US2013/038655 WO2013165902A1 (en) 2012-04-30 2013-04-29 Bromocriptine formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016202572A Division AU2016202572B2 (en) 2012-04-30 2016-04-22 Bromocriptine formulations

Publications (2)

Publication Number Publication Date
AU2013256558A1 AU2013256558A1 (en) 2014-12-18
AU2013256558B2 true AU2013256558B2 (en) 2016-01-28

Family

ID=48146046

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013256558A Ceased AU2013256558B2 (en) 2012-04-30 2013-04-29 Bromocriptine formulations
AU2016202572A Ceased AU2016202572B2 (en) 2012-04-30 2016-04-22 Bromocriptine formulations
AU2018203021A Ceased AU2018203021B2 (en) 2012-04-30 2018-05-01 Bromocriptine formulations

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2016202572A Ceased AU2016202572B2 (en) 2012-04-30 2016-04-22 Bromocriptine formulations
AU2018203021A Ceased AU2018203021B2 (en) 2012-04-30 2018-05-01 Bromocriptine formulations

Country Status (12)

Country Link
US (11) US8431155B1 (enExample)
EP (4) EP4342536B1 (enExample)
JP (1) JP6180515B2 (enExample)
KR (1) KR101593360B1 (enExample)
AR (1) AR091351A1 (enExample)
AU (3) AU2013256558B2 (enExample)
BR (1) BR112014027087B1 (enExample)
CA (1) CA2872300C (enExample)
ES (3) ES2972198T3 (enExample)
MX (2) MX363670B (enExample)
UY (1) UY34776A (enExample)
WO (1) WO2013165902A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
EP2217073B1 (en) 2007-06-21 2019-10-09 VeroScience LLC Method of treating metabolic disorders and depression with dopamine receptor agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US8431155B1 (en) 2012-04-30 2013-04-30 Veroscience Llc Bromocriptine formulations
US9682096B2 (en) 2012-05-02 2017-06-20 Janssen R & D Ireland Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections
EP3925610A1 (en) * 2016-04-20 2021-12-22 VeroScience LLC Composition and method for treating metabolic disorders
US10426772B2 (en) 2016-05-16 2019-10-01 Regents Of The University Of Minnesota Use of ergot alkaloids as an anthelmintic agent
HRP20241365T1 (hr) 2017-10-18 2024-12-20 Veroscience Llc Poboljšane formulacije bromokriptina
US11607455B2 (en) 2019-09-23 2023-03-21 Veroscience Llc Method for inducing tumor regression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017170A1 (en) * 1993-12-22 1995-06-29 Ergo Science Incorporated Accelerated release composition containing bromocriptine
WO1996013251A1 (en) * 1994-10-28 1996-05-09 R.P. Scherer Corporation Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
US20090143390A1 (en) * 2007-06-21 2009-06-04 Cincotta Anthony H Parenteral Formulations of Dopamine Agonists

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659715A (en) 1986-03-07 1987-04-21 Louisiana State University And Agricultural And Mechanical College Method of inhibiting body fat stores
US4783469A (en) 1986-03-07 1988-11-08 Meier Albert H Method of inhibiting body fat stores
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US5468755A (en) 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5744477A (en) 1988-05-10 1998-04-28 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for treatment of obesity using prolactin modulators and diet
US5830895A (en) 1988-05-10 1998-11-03 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for the determination and adjustment of prolactin daily rhythms
US6004972A (en) 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US5716932A (en) 1988-05-10 1998-02-10 Louisiana State University And Agricultural And Mechanical College Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates
US5700800A (en) 1988-05-10 1997-12-23 Ergo Science Incorporated Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
US5344832A (en) 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5668155A (en) 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US5585347A (en) 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
US5006526A (en) 1988-10-17 1991-04-09 Louisiana State University Method of treating a vertebrate animal to reduce plasma triglycerides and cholesterol levels and to alleviate and prevent atherosclerosis
IT1235053B (it) * 1989-04-07 1992-06-17 Poli Ind Chimica Spa Metodi per la preparazione di composizioni farmaceutiche a base di bromocriptina dotate di elevata stabilita' e prodotti derivanti.
CA2030174C (en) 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
US5696128A (en) 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
US5565454A (en) 1995-05-31 1996-10-15 Ergo Science, Incorporated Method for preventing intervention-associated stenosis and other symptoms associated with stenosis of blood vessels following non-bypass, invasive interventions
US5792748A (en) 1995-06-07 1998-08-11 The General Hospital Corporation Method for inhibiting neoplastic disease in mammals
US5626860A (en) 1995-06-07 1997-05-06 The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College Method for regulating metabolism with dopamine beta hydroxylase inhibitors
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US20010016582A1 (en) 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
US5877183A (en) 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040220190A1 (en) 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040077679A1 (en) 2002-07-29 2004-04-22 Cincotta Anthony H. Therapeutic treatment for the metabolic syndrome and type 2 diabetes
US20050054652A1 (en) 2002-07-29 2005-03-10 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20040081678A1 (en) 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
JP4931349B2 (ja) 2003-01-23 2012-05-16 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理およびそれに関連した使用に供するヒドロキシル化合物および組成物
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US8137993B2 (en) 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137994B2 (en) 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
EA011379B1 (ru) 2005-03-04 2009-02-27 Никомед Фарма Ас Способ получения кальциевых композиций в непрерывном псевдоожиженном слое
JP5543110B2 (ja) * 2006-01-05 2014-07-09 エッセンシャリス，インク． カリウムａｔｐチャネルオープナの塩およびその使用
WO2007119792A1 (ja) * 2006-04-13 2007-10-25 Toa Pharmaceuticals Co., Ltd. 乾式直打速崩壊性錠剤
EP2146696B1 (en) 2007-04-13 2020-01-22 Dow Global Technologies LLC Granular material for dosage forms
US20210401824A1 (en) 2007-06-21 2021-12-30 Veroscience Llc Parenteral Formulations of Dopamine Agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
EP2217073B1 (en) 2007-06-21 2019-10-09 VeroScience LLC Method of treating metabolic disorders and depression with dopamine receptor agonists
US7631155B1 (en) 2007-06-30 2009-12-08 Emc Corporation Thin provisioning of a file system and an iSCSI LUN through a common mechanism
JP2011500557A (ja) * 2007-10-11 2011-01-06 マゼンス インコーポレイテッド ナフトキノン系化合物の微粒化粒子を含有する医薬組成物
AU2010256366B2 (en) 2009-06-05 2014-08-21 Veroscience, Llc Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
EP2579876A4 (en) 2010-06-08 2013-11-27 Veroscience Llc THERAPEUTIC TREATMENT OF METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY OR PREDICT
EP2646032A4 (en) 2010-11-23 2014-04-30 Veroscience Llc THERAPEUTIC TREATMENT OF METABOLIC SYNDROME AND TYPE 2 DIABETES, ADIPOSITAS OR PREDICTES
US8431155B1 (en) 2012-04-30 2013-04-30 Veroscience Llc Bromocriptine formulations
CA2915405A1 (en) 2013-06-13 2014-12-18 Veroscience Llc Compositions and methods for treating metabolic disorders
EP3925610A1 (en) 2016-04-20 2021-12-22 VeroScience LLC Composition and method for treating metabolic disorders
US20170340271A1 (en) 2016-05-26 2017-11-30 Veroscience Llc Methods for identifying responders to dopaminergic neuronal enhancing therapies for the treatment of elevated heart rate and metabolic or cardiovascular conditions
HRP20241365T1 (hr) 2017-10-18 2024-12-20 Veroscience Llc Poboljšane formulacije bromokriptina
US11607455B2 (en) 2019-09-23 2023-03-21 Veroscience Llc Method for inducing tumor regression

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017170A1 (en) * 1993-12-22 1995-06-29 Ergo Science Incorporated Accelerated release composition containing bromocriptine
WO1996013251A1 (en) * 1994-10-28 1996-05-09 R.P. Scherer Corporation Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
US20090143390A1 (en) * 2007-06-21 2009-06-04 Cincotta Anthony H Parenteral Formulations of Dopamine Agonists

Also Published As

Publication number Publication date
US20160038424A1 (en) 2016-02-11
AR091351A1 (es) 2015-01-28
EP3620155A1 (en) 2020-03-11
AU2016202572B2 (en) 2018-02-01
AU2013256558A1 (en) 2014-12-18
BR112014027087A2 (pt) 2017-06-27
ES2755081T3 (es) 2020-04-21
EP4342536C0 (en) 2025-10-01
KR101593360B1 (ko) 2016-02-11
US11000522B2 (en) 2021-05-11
EP3620155B1 (en) 2021-10-20
HK1208173A1 (en) 2016-02-26
US20170020871A1 (en) 2017-01-26
AU2018203021B2 (en) 2020-02-06
ES2972198T3 (es) 2024-06-11
US20240131026A1 (en) 2024-04-25
EP3960160B1 (en) 2023-12-06
US20180263978A1 (en) 2018-09-20
KR20150006461A (ko) 2015-01-16
US8431155B1 (en) 2013-04-30
US20200276193A1 (en) 2020-09-03
MX363670B (es) 2019-03-29
MX2014013158A (es) 2015-07-14
US20190343833A1 (en) 2019-11-14
WO2013165902A1 (en) 2013-11-07
EP4342536B1 (en) 2025-10-01
US9993474B2 (en) 2018-06-12
AU2018203021A1 (en) 2018-05-24
US9700555B2 (en) 2017-07-11
US8613947B2 (en) 2013-12-24
UY34776A (es) 2013-11-29
ES2902573T3 (es) 2022-03-29
US20170340632A1 (en) 2017-11-30
EP4342536A2 (en) 2024-03-27
AU2016202572A1 (en) 2016-05-19
US20130287848A1 (en) 2013-10-31
US20140187560A1 (en) 2014-07-03
JP2015515984A (ja) 2015-06-04
BR112014027087B1 (pt) 2021-03-02
EP2844229B1 (en) 2019-09-11
US20210228576A1 (en) 2021-07-29
EP4342536A3 (en) 2024-06-26
MX2019003619A (es) 2019-07-18
US9192576B2 (en) 2015-11-24
US11666567B2 (en) 2023-06-06
CA2872300A1 (en) 2013-11-07
US9522117B2 (en) 2016-12-20
US10307421B2 (en) 2019-06-04
JP6180515B2 (ja) 2017-08-16
EP3960160A1 (en) 2022-03-02
EP2844229A1 (en) 2015-03-11
US10688094B2 (en) 2020-06-23
CA2872300C (en) 2016-08-16

Similar Documents

Publication Publication Date Title
US11666567B2 (en) Bromocriptine formulations
HK40026299A (en) Bromocriptine formulations
HK40026299B (en) Bromocriptine formulations
HK1208173B (en) Bromocriptine formulations

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired